BioHarvest Q2 Revenue Hits $8.8M, Gross Margin 58%; CDMO Deal Secures 20-Ton Fragrance Production
BHST sits 27% above its 52-week low of $1.82 on elevated volume (2.4× avg).
Summary
BioHarvest reported Q2 2026 revenue of $8.8 million, up 3.8% year-over-year, with gross margins holding at 58%. Operating loss widened to $2.5 million from $1.8 million, driven by increased CDMO division spending. Net loss narrowed to $3.7 million from $4.1 million. The company is deliberately prioritizing gross margin and cash discipline in its consumer business, redirecting capital to manufacturing capacity. This follows the morning's announcement of a 20-ton manufacturing and supply agreement for a rare fragrance compound, which management sees as a model for future high-margin recurring revenue. The CDMO deal, with limited production possible by H1 2027, validates the Botanical Synthesis platform's commercial potential. The $1.4 million Israel Innovation Authority grant and saffron program advancement add to the pipeline momentum.
At the time of this announcement, BHST was trading at $2.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.6M. The 52-week trading range was $1.82 to $12.80. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.